Deals this week: Teva Pharmaceuticals, Boston Children’s Hospital, Lab Genomics

1 December 2016 (Last Updated December 1st, 2016 18:30)

Teva Pharmaceuticals Industries Ltd has entered a co-marketing agreement with Syqe Medical Ltd, a medicinal plant inhaler developer.

Teva Pharmaceuticals Industries Ltd has entered a co-marketing agreement with Syqe Medical Ltd, a medicinal plant inhaler developer.

According to the agreement, Teva Pharmaceuticals will be responsible to market cannabis with Syqe Medical’s selective-dose medicinal plant inhaler.

The agreement allows the two partners to introduce cannabis inhaler for pain management in Israel.

Boston Children’s Hospital and GE Healthcare Ltd, a medical device company, have entered an agreement to further advance the diagnosis of brain diseases in children.

According to the agreement, both the partners will develop and commercialise digital diagnostic solutions to diagnose brain disorders.

Lab Genomics, a molecular diagnostics products provider, plans to raise $8.54m through the private placement of convertible bonds due 2 December 2021.

"According to the agreement, both the partners will develop and commercialise digital diagnostic solutions to diagnose brain disorders."

The company plans to invest the funds for general corporate purposes.

Annidis Corporation, a retinal imaging technology product provider, plans for a private placement of 43 million of its common stock shares to raise $1.62m.

The company intends to use the funds to increase the working capital.


Image: Teva Pharmaceuticals Industries Ltd has entered a co-marketing agreement with Syqe Medical. Image courtesy of Wikimedia Commons.